Enhanced cellular uptake of albumin-based lyophilisomes when functionalized with cell-Penetrating peptide tat in hela cells

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Van Bracht, Etienne ^a   Versteegden, Luuk R M ^a   Stolle, Sarah ^c   Verdurmen, Wouter P R ^d   Woestenenk, Rob ^b   Raavé, René ^a   Hafmans, Theo ^a   Oosterwijk, Egbert ^a   Brock, Roland ^a   Van Kuppevelt, Toin H ^a   Daamen, Willeke F ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CELL PENETRATING PEPTIDE; CYSTEINE; DRUG CARRIER; LYOPHILISOME; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; BOVINE SERUM ALBUMIN;

ARTICLE; CACO 2 CELL LINE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HELA CELL LINE; INTERNALIZATION; PARTICLE SIZE; PHAGOCYTOSIS; PINOCYTOSIS; TRANSMISSION ELECTRON MICROSCOPY; AMINO ACID SEQUENCE; ANIMAL; BOVINE; CHEMISTRY; ENDOCYTOSIS; FLOW CYTOMETRY; FREEZE DRYING; HUMAN; METABOLISM; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CACO-2 CELLS; CATTLE; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; ENDOCYTOSIS; FLOW CYTOMETRY; FREEZE DRYING; HELA CELLS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; SERUM ALBUMIN, BOVINE;

EID: 84927544100     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110813     Document Type: Article

References (49)

1. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
2. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26: 57-64.
3. Danhier F, Ansorena E, Silva JM, Coco R, Le BA, et al. (2012) PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 161: 505-522.
4. Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63: 131-135.
5. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316.
6. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60: 1615-1626.
7. De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 3: 133-149.
8. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, et al. (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180.
9. Elzoghby AO, Samy WM, Elgindy NA (2012) Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release.
10. Daamen WF, Geutjes PJ, Nillesen STM, Van Moerkerk HTB, Wismans R, et al. (2007) Lyophilisomes: A new type of (bio)capsules. Adv Mater 19: 673-677.
11. van Bracht E, Raave R, Verdurmen WP, Wismans RG, Geutjes PJ, et al. (2012) Lyophilisomes as a new generation of drug delivery capsules. Int J Pharm 439: 127-135.
12. van Bracht E, Stolle S, Hafmans TG, Boerman OC, Oosterwijk E, et al. (2014) Specific targeting of tumor cells by lyophilisomes functionalized with antibodies. Eur J Pharm Biopharm.
13. Elzoghby AO, Samy WM, Elgindy NA (2011) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release.
14. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, et al. (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8: 1038-1044.
15. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, et al. (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23: 6019-6026.
16. Feinstein SB, Cheirif J, Ten Cate FJ, Silverman PR, Heidenreich PA, et al. (1990) Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results. J Am Coll Cardiol 16: 316-324.
17. Geny B, Mettauer B, Muan B, Bischoff P, Epailly E, et al. (1993) Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol 22: 1193-1198.
18. Koren E, Torchilin VP (2012) Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 18: 385-393.
19. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57: 579-596.
20. Massodi I, Bidwell GL III, Raucher D (2005) Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 108: 396-408.
21. Striab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL (2002) Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 19: 744-754.
22. Torchilin VP (2008) Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90: 604-610.
23. Qin Y, Chen H, Zhang Q, Wang X, Yuan W, et al. (2011) Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 420: 304-312.
24. Sawant RR, Torchilin VP (2009) Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 374: 114-118.
25. Patel LN, Zaro JL, Shen WC (2007) Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res 24: 1977-1992.
26. Chugh A, Eudes F, Shim YS (2010) Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living cells. IUBMB Life 62: 183-193.
27. Frankel AD (1992) Activation of HIV transcription by Tat. Curr Opin Genet Dev 2: 293-298.
28. Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017.
29. Garza-Licudine E, Deo D, Yu S, Uz-Zaman A, Dunbar WB (2010) Portable nanoparticle quantization using a resizable nanopore instrument - The IZON qNano. Conf Proc IEEE Eng Med Biol Soc 2010: 5736-5739.
30. Tario JD Jr., Gray BD, Wallace SS, Muirhead KA, Ohlsson-Wilhelm BM, et al. (2007) Novel lipophilic tracking dyes for monitoring cell proliferation. Immunol Invest 36: 861-885.
31. Wallace PK, Tario JD Jr., Fisher JL, Wallace SS, Ernstoff MS, et al. (2008) Tracking antigen-driven responses by flow cytometry: Monitoring proliferation by dye dilution. Cytometry A 73: 1019-1034.
32. Nuutila J, Lilius EM (2005) Flow cytometric quantitative determination of ingestion by phagocytes needs the distinguishing of overlapping populations of binding and ingesting cells. Cytometry A 65: 93-102.
33. Ramarao N, Meyer TF (2001) Helicobacter pylori resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescenceactivated cell sorting. Infect Immun 69: 2604-2611.
34. Orr G, Panther DJ, Cassens KJ, Phillips JL, Tarasevich BJ, et al. (2009) Syndecan-1 mediates the coupling of positively charged submicrometer amorphous silica particles with actin filaments across the alveolar epithelial cell membrane. Toxicol Appl Pharmacol 236: 210-220.
35. Oh E, Delehanty JB, Sapsford KE, Susumu K, Goswami R, et al. (2011) Cellular uptake and fate of PEGylated gold nanoparticles is dependent on both cellpenetration peptides and particle size. ACS Nano 5: 6434-6448.
36. Xia H, Gao X, Gu G, Liu Z, Hu Q, et al. (2012) Penetratin-functionalized PEGPLA nanoparticles for brain drug delivery. Int J Pharm.
37. Liu BR, Li JF, Lu SW, Leel HJ, Huang YW, et al. (2010) Cellular internalization of quantum dots noncovalently conjugated with arginine-rich cell-penetrating peptides. J Nanosci Nanotechnol 10: 6534-6543.
38. Tyagi M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276: 3254-3261.
39. Gump JM, Dowdy SF (2007) TAT transduction: The molecular mechanism and therapeutic prospects. Trends Mol Med 13: 443-448.
40. Lei T, Srinivasan S, Tang Y, Manchanda R, Nagesetti A, et al. (2011) Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine 7: 324-332.
41. Vieira OV, Botelho RJ, Grinstein S (2002) Phagosome maturation: Aging gracefully. Biochem J 366: 689-704.
42. Geisow MJ (1984) Fluorescein conjugates as indicators of subcellular pH. A critical evaluation. Exp Cell Res 150: 29-35.
43. Brandhonneur N, Chevanne F, Vie V, Frisch B, Primault R, et al. (2009) Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 36: 474-485.
44. Gupta B, Levchenko TS, Torchilin VP (2005) Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57: 637-651.
45. Tseng YL, Liu JJ, Hong RL (2002) Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: A kinetic and efficacy study. Mol Pharmacol 62: 864-872.
46. Wang J, Byrne JD, Napier ME, Desimone JM (2011) More effective nanomedicines through particle design. Small 7: 1919-1931.
47. Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G (2004) OVCAR- 3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta 1665: 48-56.
48. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY (2009) Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 1: 371-381.
49. MacEwan SR, Chilkoti A (2013) Harnessing the power of cell-penetrating peptides: Activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5: 31-48.